Neuclone Makes Progress With Ustekinumab Trial

Australian Firm Hails Phase I Results For Stelara Rival

Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.

Phase_One
NeuClone has reported progress in its Phase I trial for ustekinumab • Source: Shutterstock

More from Biosimilars

More from Products